Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing setting
2019
Purpose
To determine the exposure–response (ER) relationships between atezolizumab exposure and efficacy or safety in patients with advanced non-small cell lung cancer (NSCLC) or urothelial carcinoma (UC) and to identify alternative dosing regimens.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
29
References
29
Citations
NaN
KQI